

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL EL 990504803 US

No.:

APPLICANT(s): SUNDERMANN et al.

SERIAL NO.:

ART UNIT:

FILING DATE: Herewith

EXAMINER:

TITLE: SUBSTITUTED 1-PHENETHYLPIPERIDINE COMPOUNDS
USED AS INTER ALIA ANALGESICS

ATTORNEY

DOCKET NO.: 785-011641-US(C01)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

(37 C.F.R. §1.97(b)(1))

Sir:

This Information Disclosure Statement is filed together with the above-identified patent application. Thus, a certification under 37 C.F.R. 1.97 (e) or fee under 37 C.F.R. 1.17(p) is not required for the information herein to be considered.

The following information is being disclosed to the Patent and Trademark Office as information that may be

material to the examination of the above-identified patent application.

The above-identified patent application claims priority to German Patent Application No. 10132746.3 filed July 5, 2001 and claims the benefit of PCT International Application No. PCT/EP02/07379 filed July 3, 2002. Applicants' attorney encloses a copy of a German Search Report issued on the priority German Patent Application No. 10132746.3 and a PCT International Search Report issued on the corresponding PCT International Application No. PCT/EP02/07379. The German Search Report cited German Patent Application No. DE 3226540 A1 and European Patent Application No. EP 1182193 A1. The PCT International Search Report cited United States Patent Nos. US 4,248,877 and US 5,446,052 and "Synthesis and Pharmacological Studies Of 4, 4-Disubstituted Piperidines: A New Class Of Compounds With Potent Analgesic Properties", Huegi et al., Journal of Medicinal Chemistry, American Chemical Society, 1983, 26, pp. 42-50.

Applicants' attorney also mentions at this time German Patent Application No. 2265193; "Automated Docking of 82 N-Benzylpiperidine Derivatives To Mouse Acetylcholinesterase and Comparative Molecular Field Analysis With 'Natural' Alignment", Bernard et al., Journal of Computer-Aided Molecular Design, 1999, 13, pp.355-371; and "Antagonism Of The Frequency Of Phenylquinone-Induced Writing In The Mouse By Weak Analgesics And Nonanalgesics", Hendershop et al., Vol. 125, pp. 237-240, which were cited in the specification of the above-identified patent application.

Pursuant to Sections 609 and 707.05(b) of the MPEP and 37 C.F.R. 1.97-1.99, the undersigned is bringing the following co-pending U.S. patent applications of which he is aware, to the attention of the Examiner in the above-identified application as they may be considered pertinent to the invention claimed in the above-identified application.


- (1) Express Mail No.: EL 990504542 US
Mailing Date: January 5, 2004
Title: Substituted 1-Aryl-But-3-Enylamine
And 1-Aryl-But-2-Enylamine Compounds
Assignee: Grunenthal GmbH et al.
Attorney Docket No.: 785-011630-US(C01)
- (2) Express Mail No.: EL 990504794 US
Mailing Date: January 5, 2004
Title: Substituted γ -Lactone Compounds As
NMDA-Antagonists
Assignee: Grunenthal GmbH
Attorney Docket No.: 785-011640-US(C01)
- (4) Express Mail No.: EL 990504539 US
Mailing Date: January 5, 2004
Title: Use Of Substituted Gamma-Lactone Compounds
As Pharmaceutical Preparations
Assignee: Grunenthal GmbH
Attorney Docket No.: 785-011642-US(C01)

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to

be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any additional fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,



Clarence A. Green

Reg. No.: 24,622

PERMAN & GREEN, LLP

425 Post Road, Fairfield, CT 06824

(203) 259-1800

Customer No.: 2512

5 January 2004
Date

**INFORMATION DISCLOSURE
CITATION FORM FOR
PATENT APPLICATION
(FORM PTO-1449)
(Substitute)**

Docket No.: 785-011641-US (C01)

Serial No.:

Applicant(s):

Filing Date: Herewith

Group:

U.S. PATENTS

Initials	Patent Number	Issue Date	Name	Class	Sub-class	Filing date
	5,446,052	8/29/95	Emonds-Alt et al.	514	318	2/4/94
	4,248,877	2/3/81	Rissi et al	424	267	2/22/79

U.S. PATENT PUBLICATIONS

Initials	Publication No.	Pub. Date	Name	Class	Sub-class	Filing Date

FOREIGN PATENT DOCUMENTS

Initials	Document Number	Date	Country	Name	Translation? Yes/No/n/a
	DE 32 26 540 A1	2/3/83	Germany	Bristol-Myers Co.	no
	DT 22 65 193 A1	12/30/76	Germany	Buskine S.A.	no
	EP 1 182 193 A1	2/27/02	Europe	Mochida Pharmaceutical Co., LTD	n/a

OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)

	"Automated Docking of 82 N-Benzylpiperidine Derivatives To Mouse Acetylcholinesterase and Comparative Molecular Field Analysis With 'Natural' Alignment", Bernard et al., Journal of Computer-Aided Molecular Design, 1999, 13, pp.355-371; and
	"Antagonism Of The Frequency Of Phenylquinone-Induced Writing In The Mouse By Weak Analgesics And Nonanalgesics", Hendershop et al., Vol. 125, pp. 237-240,
	"Synthesis and Pharmacological Studies Of 4, 4-Disubstituted Piperidines: A New Class Of Compounds With Potent Analgesic Properties", Huegi et al., Journal of Medicinal Chemistry, American Chemical Society, 1983, 26, pp. 42-50.

Examiner's Signature:

Date Considered:

Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered.
Include a copy of this citation form with your next correspondence to the Applicant(s).